Ongoing study - Medical progress does not stand still. Every year many new pharmaceuticals and other interventions are introduced on the market. In a context of limited budgetary means, the reimbursement of certain pharmaceutical specialties can mean that other healthcare interventions cannot be reimbursed (anymore). This is the so-called ‘displacement effect'. The KCE will examine the extent to which the expenditure in the last years on new pharmaceutical specialties in the field of oncology results in health gains.